Abstracts tagged "methotrexate (MTX) and registry"

Abstract Number: 1397 • 2019 ACR/ARP Annual Meeting
Comparative Effectiveness of Tocilizumab in Combination with Methotrexate versus Tumor Necrosis Factor Inhibitors (TNFis) in Combination with Methotrexate in Patients with Rheumatoid Arthritis with Prior Exposure to TNFis
Dimitrios Pappas¹, Taylor Blachley ², Steve Zlotnick ³, Jennie Best ³, Kelechi Emeanuru ² and Joel Kremer ⁴, ¹Columbia University, New York, NY, ²Corrona, LLC, Waltham, MA, ³Genentech, Inc., South San Francisco, CA, ⁴Albany Medical College and The Center for Rheumatology; Corrona, LLC, Albany, NY
Background/Purpose: Clinical studies have demonstrated the efficacy of tocilizumab (TCZ) administered with methotrexate (MTX) in improving rheumatoid arthritis (RA) disease activity in patients who have…
Abstract Number: 2333 • 2017 ACR/ARHP Annual Meeting
Adjudication of Infections from the Pharmacovigilance in Juvenile Idiopathic Arthritis Patients (PHARMACHILD) Treated with Biologic Agents and/or Methotrexate with a Focus on Opportunistic Infections
Joost Swart¹, Gabriella Giancane^1,2, Elio Castagnola¹, Andreas Groll¹, Gerd Horneff¹, Hans-Iko Huppertz¹, Daniel J Lovell³, Tom Wolfs¹, Michaël Hofer¹, Ekaterina Alexeeva¹, Violeta Vladislava Panaviene¹, Susan Nielsen¹, Jordi Anton¹, Florence Uettwiller¹, Valda Stanevicha¹, Maria Trachana¹, Fabrizio De Benedetti¹, Constantin Ailioaie¹, Elena Tsitsami¹, Sylvia S.M. Kamphuis¹, Troels Herlin¹, Pavla Dolezalová¹, Gordana Susic¹, Berit Flato¹, Flavio Sztajnbok¹, Elena Fueri⁴, Francesca Bovis⁵, Francesca Bagnasco¹, Angela Pistorio¹, Alberto Martini⁶, Nico Wulffraat⁷ and Nicolino Ruperto⁶, ¹Istituto Giannina Gaslini - Pediatria II, Reumatologia - PRINTO, Genoa, Italy, ²Pediatria II, Reumatologia - PRINTO, Istituto Giannina Gaslini - Pediatria II, Reumatologia - PRINTO, Genova, Italy, ³Rheumatology, PRCSG - Cincinnati Children's Hospital Medical Center, Cinncinnati, OH, ⁴Istituto Giannina Gaslini - Pediatria II, Reumatologia - PRINTO, Genova, Italy, ⁵Università degli Studi di Genova, Genoa, Italy, ⁶Istituto Giannina Gaslini, Genoa, Italy, ⁷Pediatric rheumatology, Wilhelmina Children's Hospital/ UMC Utrecht, Utrecht, Netherlands
Background/Purpose: Pharmachild is a pharmacovigilance registry on children with JIA treated mainly with biologics ± methotrexate (MTX). Little evidence exists in literature about the role…
Abstract Number: 3116 • 2016 ACR/ARHP Annual Meeting
Risk of Infections in Juvenile Idiopathic Arthritis Patients Treated with Biologic Agentsand/or Methotrexate: Results from Pharmachild Registry
Gabriella Giancane¹, Joost Swart², Francesca Bovis², Elio Castagnola², Andreas Groll², Gerd Horneff², Hans-Iko Huppertz², Daniel J. Lovell², Tom Wolfs², Michaël Hofer², Ekaterina Alexeeva², Violeta Vladislava Panaviene², Susan Nielsen², Jordi Anton², Florence Uettwiller², Valda Stanevicha², Maria Trachana², Denise Pires Marafon³, Constantin Ailioaie², Elena Tsitsami², Sylvia S.M. Kamphuis², Troels Herlin², Pavla Dolezalová³, Gordana Susic², Berit Flato², Flavio Sztajnbok², Angela Pistorio¹, Alberto Martini², Nico Wulffraat² and Nicolino Ruperto², ¹Pediatria II, Reumatologia, PRINTO, Istituto Giannina Gaslini, Genoa, Italy, ²Istituto Giannina Gaslini, Genoa, Italy, ³Istituto Giannina Gaslini, genoa, Italy
Background/Purpose: Pharmachild is an international registry involving over 100 the Paediatric Rheumatology INternational Trials Organisation (PRINTO)/ the Paediatric Rheumatology European Society (PRES) centres in 38 countries. The registry was set up to evaluate long term safety and efficacy…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].